Table 1.
Demographic and clinical characteristics of self‐identified African American study subjects
| All Subjects | No Cancer on Biopsy | Diagnosed with GS 6 Cancer | Diagnosed with GS 7‐10 Cancer | |
|---|---|---|---|---|
| Number of Subjects | 96 | 47 | 21 | 28 |
| Age at biopsy | ||||
| Mean (SD) | 61.1 (7.6) | 61.9 (7.0) | 60.6 (9.0) | 60.2 (7.6) |
| Median | 61.5 | 63.0 | 61.0 | 60.5 |
| Gleason Sum (GS) | ||||
| Grade Group 1 | 21 | na | 21 | 0 |
| Grade Group 2 | 16 | na | 0 | 16 |
| Grade Group 3 | 5 | na | 0 | 5 |
| Grade Group 4‐5 | 7 | na | 0 | 7 |
| NCCN Risk | ||||
| Low or very low | 20 | na | 20 | 0 |
| Intermediate | 20 | na | 1 | 19 |
| High | 9 | na | 0 | 9 |
| Serum PSA (ng/mL)a | ||||
| Mean (SD) | 7.84 (7.40) | 7.03 (6.10) | 5.53 (2.37) | 11.03 (10.57) |
| Median | 5.60 | 5.55 | 5.58 | 6.20 |
| Prostate Size (cc)b | ||||
| Mean (SD) | 49.0 (33.7) | 58.8 (41.6) | 41.7 (19.3) | 38.6 (21.7) |
| Median | 40 | 48.0 | 37.0 | 34.6 |
| PSA Densityc | ||||
| Mean (SD) | 0.21 (0.23) | 0.16 (0.19) | 0.15 (0.09) | 0.33 (0.31) |
| Median | 0.13 | 0.12 | 0.12 | 0.21 |
a
One man with a PSA of 2196 ng/mL is excluded.
b
For one man, prostate volume was missing from the clinical record.
c
One man with a PSA of 2196 ng/mL and a second man for whom prostate volume was missing are excluded.